IGEA appoints new Chief Financial Officer

Hoofddorp, the Netherlands, 08 December 2022. IGEA Pharma N.V. (SIX: IGPH) today appointed Diego Fiorentini as new CFO of IGEA Pharma, filling a void that was ad interim covered by the previous CEO.

Read More

Minutes of the AGM 1 December 2022

Minutes of the Annual General Meeting (the ‘Meeting‘) of IGEA Pharma N.V., a public limited company (naamloze vennootschap), having its registered office in Amsterdam (the Netherlands), and address at: (2132 WT) Hoofddorp, Siriusdreef 17, registered with the Commercial Register of the Chamber of Commerce under number 70212821 (the ‘Company‘), held via (i) Zoom and (ii) in the meeting room next to the Company’s office with address at Hoofddorp Transpolis, Polarisavenue 1, (2123 JH) Hoofddorp (the Netherlands) on 1 December 2022 at 11.00 hours CEST.

Read More

IGEA Pharma has announced that LMH – an industrial holding company – has completed the due diligence process for a euro 6.000.000 committment to fund the swiss CBD extraction facility

Hoofddorp, the Netherlands, 13th July 2022. Today IGEA Pharma N.V. (SIX: IGPH) has announced that LMH Holding has completed the due diligence process on the Company in relation to its Euro 6.0 million commitment to fund the GMP-Pharma CBD extraction facility owned through its joint-venture Blue Sky Swisse S.A.

Read More